The second cohort only included patients with stage IV melanoma who were predominantly (> 85%) treated with PD1 inhibitors across three US melanoma institutions and was enriched for patients with APC/CTNNB1 mutations (25%, retrospective chart review analysis). Here, CTNNB1 is linked to melanoma.